DGAP-News: Apricus Biosciences Announces Third Quarter 2013 Corporate Update Conference Call
(firmenpresse) - Apricus Biosciences, Inc.
05.11.2013 17:37
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Wednesday, November 13, 2013 at 9:00 AM ET
SAN DIEGO, 2013-11-05 17:37 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that it will hold a conference call to
discuss its recent corporate highlights on Wednesday, November 13, 2013 at 9:00
AM ET. Apricus will provide a full update on its lead product Vitaros(r) and its
product candidate Femprox(r).
The call can be accessed in the U.S. by dialing 877-407-9210 and outside of the
U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus
Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171856. The teleconference
replay will be available for one week by dialing in the U.S. 877-660-6853 and
outside of the U.S. by dialing 201-612-7415. Replay Passcode 13572631 is
required for playback. The webcast replay will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros(r), for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus' marketing partners, which include Abbott
Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
(Sandoz) and Bracco SpA. Femprox(r), the Company's product candidate for the
treatment of female sexual interest/arousal disorder, has successfully
completed a nearly 400-subject proof-of-concept study.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Apricus Investor Relations:
David Pitts or Lourdes Catala
Argot Partners
212-600-1902
david(at)argotpartners.com
lourdes(at)argotpartners.com
News Source: NASDAQ OMX
05.11.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2013 - 17:37 Uhr
Sprache: Deutsch
News-ID 312958
Anzahl Zeichen: 3469
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Announces Third Quarter 2013 Corporate Update Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
